Prestige Consumer Healthcare vs Perrigo
PBH and PRGO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PBH and PRGO compare
Prestige Consumer Healthcare and Perrigo are about the same size, with market caps of $2.3B and $2.2B.
Prestige Consumer Healthcare grew revenue faster over the last twelve months (−1.4% versus −4.2% for Perrigo).
Prestige Consumer Healthcare keeps more of each dollar of sales as profit, with a net margin of 15.6% compared with −41.9% at Perrigo.
Perrigo pays a dividend yielding 5.5%; Prestige Consumer Healthcare does not pay one.
Prestige Consumer Healthcare scores higher on the StockData Score (12 against 9 for Perrigo), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PBH | PRGO |
|---|---|---|
| Size and price | ||
| Market cap | $2.3B | $2.2B |
| Share price | $48.22 | $15.76 |
| Change, 1 year | −19.6% | 14.4% |
| Change, 5 years | −14.5% | −58.3% |
| Beta (5Y) | 0.74 | 2.02 |
| Employees | 890 | 8,100 |
| StockData Score | ||
| Total score | 12 (better) | 9 |
| Valuation score | 5 (better) | 2 |
| Growth score | 1 (better) | 0 |
| Performance score | 4 (better) | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 13.5× | – |
| P/S | 2.1× | 0.5× (better) |
| P/B | 1.2× | 0.9× (better) |
| EV/EBITDA | 13.1× | – |
| P/FCF | 9.7× (better) | 18.3× |
| FCF yield | 10.3% (better) | 5.5% |
| Fair value | $63.54 | $17.50 |
| Margin of safety | 24.1% (better) | 10.0% |
| Growth | ||
| Revenue growth (TTM) | −1.4% (better) | −4.2% |
| Revenue growth, 5Y average | 2.9% (better) | 0.79% |
| Net income growth (TTM) | −19.2% | – |
| EPS growth (TTM) | −16.2% | – |
| EPS growth, 5Y average | 3.8% | – |
| Profitability | ||
| Gross margin | 53.5% (better) | 33.3% |
| Operating margin | 26.3% (better) | −37.7% |
| Net margin | 15.6% (better) | −41.9% |
| FCF margin | 21.3% (better) | 2.9% |
| Return on equity | 9.1% (better) | −49.6% |
| Return on invested capital | 8.2% (better) | −18.9% |
| Financial health | ||
| Debt / equity | 1.05 (better) | 1.31 |
| Net debt / EBITDA | 5.98 | – |
| Current ratio | 3.23 (better) | 2.32 |
| Altman Z-score | 1.60 (better) | −0.39 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Dividend yield | – | 5.5% |
| Years of dividend growth | – | 11 |
| Dividend growth, 5Y average | – | 5.2% |
| Buyback yield | 5.3% | – |
| Shareholder yield | 5.3% | 5.5% (better) |
| Ownership | ||
| Held by institutions | 113% | 116% |
| Held by insiders | 1.4% | 0.36% |
| Insider net buying, 12 months | −$203K | $0 (better) |
| Short interest, % of float | 9.1% | 17.8% |
Go deeper
- PBH stock overview
- PBH income statement
- PBH valuation and score
- PRGO stock overview
- PRGO income statement
- PRGO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.